Gan & Lee Pharmaceuticals Co Ltd (stock code: 603087.SH), a global biopharmaceutical company, announced on Wednesday that it has received orphan drug status from the European Medicines Agency (EMA) for the investigational drug GLR2007 intended to treat gliomas neuroepithelial tumours that originate from glial cells in the central nervous system.
The company's present clinical development program for GLR2007, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, is exploring the treatment of advanced solid tumours that has the potential to offer treatment options for clinicians and patients.
The product has received Orphan drug status in the European Union based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval